rivaroxaban alembic õhukese polümeerikattega tablett
alembic pharmaceuticals europe limited - rivaroksabaan - õhukese polümeerikattega tablett - 2,5mg 168tk; 2,5mg 28tk; 2,5mg 30tk; 2,5mg 14tk; 2,5mg 56tk; 2,5mg 98tk; 2,5mg 196tk
kardatuxan õhukese polümeerikattega tablett
gedeon richter plc. - rivaroksabaan - õhukese polümeerikattega tablett - 2,5mg 90tk
rivaroxaban stada õhukese polümeerikattega tablett
stada arzneimittel ag - rivaroksabaan - õhukese polümeerikattega tablett - 2,5mg 98tk; 2,5mg 42tk; 2,5mg 20tk; 2,5mg 10tk; 2,5mg 196tk; 2,5mg 28tk; 2,5mg 56tk
xaboplax õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - rivaroksabaan - õhukese polümeerikattega tablett - 2,5mg 5tk
prasugrel alembic õhukese polümeerikattega tablett
alembic pharmaceuticals europe limited - prasugreel - õhukese polümeerikattega tablett - 5mg 56tk; 5mg 30tk; 5mg 84tk; 5mg 14tk; 5mg 98tk; 5mg 28tk
xerdoxo õhukese polümeerikattega tablett
krka, d.d., novo mesto - rivaroksabaan - õhukese polümeerikattega tablett - 2,5mg 28tk; 2,5mg 98tk; 2,5mg 56tk; 2,5mg 100tk; 2,5mg 14tk; 2,5mg 10tk; 2,5mg 30tk
xanirva kõvakapsel
zentiva k.s. - rivaroksabaan - kõvakapsel - 2,5mg 100tk; 2,5mg 28tk; 2,5mg 56tk
rivaroxaban accord
accord healthcare s.l.u. - rivaroksabaan - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombootilised ained - täiskasvanud patsientidel, kellele tehti plaaniline puusa- või põlveliigese asendamise operatsiooni venoosse trombemboolia (vte) ennetamine. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 haemodynamically ebastabiilne pe patsientidel). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 ja 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
razarxo õhukese polümeerikattega tablett
tad pharma gmbh - rivaroksabaan - õhukese polümeerikattega tablett - 2,5mg 30tk; 2,5mg 90tk; 2,5mg 28tk; 2,5mg 15tk; 2,5mg 14tk; 2,5mg 98tk; 2,5mg 10tk; 2,5mg 60tk
possia
astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - antitrombootilised ained - possia, koos atsetüülsalitsüülhappega (ash), on näidustatud aterotrombootiliste juhtumite ennetamiseks täiskasvanud patsientidel, kellel on äge koronaarsündroom (ebastabiilne stenokardia, st-elevatsioonita müokardiinfarkt [nstemi] või st-elevatsiooniga müokardiinfarkt [stemi]); patsiendile meditsiiniliselt õnnestus, ja need, kes on koos perkutaanse koronaarse interventsiooni (pci) või koronaararterite šunteerimine (cabg).